Taken together, these data confirmed that both human cell lines used in this study (1) are of the myeloid lineage based on their expression of CD45 and myeloid markers CD33 and CD13; (2) represent two categories of patients: newly diagnosed AML patients (HL-60) and relapsed AML patients (Molm-14) based on the origin of the patient samples; and (3) represent CD13 low and CD13 high AML subtypes. This evidence concerns the gene ANPEP and acute myeloid leukemia.